Kanghong Pharma receives approval for KHN702 clinical trial

Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SZSE:002773) announced today that it has received a drug clinical trial approval notice from the National Medical Products Administration for its KHN702 tablets. The drug, classified as a Category 1 chemical drug, is intended for the treatment of acute pain. KHN702 is a novel, highly selective NaV1.8 inhibitor developed independently by Kanghong Pharma, with no addictive properties. Preclinical studies have demonstrated good safety and therapeutic effects in various pain models, suggesting promising clinical applications. The company cautioned that the research, clinical trial, and approval processes involve uncertainties and advised investors to exercise caution.